Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D3, and vitamin K1 produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome

Nutrition Research

Volumn 31, Issue 5, 2011, Pages 347-355

  Lamb, Joseph J ^a   Holick, Michael F ^b   Lerman, Robert H ^a   Konda, Veera R ^a   Minich, Deanna M ^a   Desai, Anuradha ^a   Chen, Tai C ^b   Austin, Melissa ^a   Kornberg, Jacob ^a   Chang, Jyh Lurn ^a   Hsi, Alex ^a   Bland, Jeffrey S ^a   Tripp, Matthew L ^a  

^a Metagenics Inc   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone turnover; Dietary supplement; Humulus lupulus; Kinase modulation; Mediterranean diet; Osteocalcin; Phytochemicals; Postmenopausal women; Randomized clinical trial

Indexed keywords

BERBERINE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; OSTEOCALCIN; PHYTOMENADIONE; SOMATOMEDIN C;

ADULT; AEROBIC EXERCISE; AGED; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GLYCEMIC LOAD; HUMAN; LOW CARBOHYDRATE DIET; MEDITERRANEAN DIET; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT;

ANTI-INFLAMMATORY AGENTS; BERBERINE; BIOLOGICAL MARKERS; BONE AND BONES; CHOLECALCIFEROL; COLLAGEN TYPE I; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HUMULUS; INSULIN-LIKE GROWTH FACTOR I; METABOLIC SYNDROME X; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOTHERAPY; PLANT EXTRACTS; SINGLE-BLIND METHOD; VITAMIN D; VITAMIN K 1; VITAMINS;

HUMULUS LUPULUS;

EID: 79957683656     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2011.03.016     Document Type: Article

References (49)

1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
2. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-436.
3. Lin J.W., Caffrey J.L., Chang M.H., Lin Y.S. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality-cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2010, 95:4258-4267.
4. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
5. Boyce B.F., Aufdemorte T.B., Garrett I.R., Yates A.J., Mundy G.R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989, 125:1142-1150.
6. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe E., Nakamura Y., et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990, 145:3297-3303.
7. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
8. McFarlane S.I. Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights. J Cardiometab Syndr 2006, 1:53-57.
9. Cashman K.D. Diet, nutrition, and bone health. J Nutr 2007, 137:2507S-2512S.
10. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
11. Lamb J.J., Williams S.E. Metabolic bone disease. Food and nutrients in disease management 2009, 521-537. CRC Press, Boca Raton, FL. I. Kohlstadt (Ed.).
12. Prynne C.J., Mishra G.D., O'Connell M.A., Muniz G., Laskey M.A., Yan L., et al. Fruit and vegetable intakes and bone mineral status: a cross sectional study in 5 age and sex cohorts. Am J Clin Nutr 2006, 83:1420-1428.
13. McTiernan A., Wactawski-Wende J., Wu L., Rodabough R.J., Watts N.B., Tylavsky F., et al. Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr 2009, 89:1864-1876.
14. Qi L., Hu F.B. Dietary glycemic load, whole grains, and systemic inflammation in diabetes: the epidemiological evidence. Curr Opin Lipidol 2007, 18:3-8.
15. Esposito K, Giugliano D. Mediterranean diet and the metabolic syndrome: the end of the beginning. Metab Syndr Relat Disord 8:197-200.
16. Rumawas M.E., Meigs J.B., Dwyer J.T., McKeown N.M., Jacques P.F. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. Am J Clin Nutr 2009, 90:1608-1614.
17. Rosato M.T., Schneider S.H., Shapses S.A. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int 1998, 63:107-111.
18. Cashman K.D. Altered bone metabolism in inflammatory disease: role for nutrition. Proc Nutr Soc 2008, 67:196-205.
19. Holick M.F., Lamb J.J., Lerman R.H., Konda V.R., Darland G., Minich D.M., et al. Hop rho iso-alpha acids, berberine, vitamin D(3) and vitamin K (1) favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. J Bone Miner Metab 2009, 28:342-350.
20. Babish J.G., Pacioretty L.M., Bland J.S., Minich D.M., Hu J., Tripp M.L. Antidiabetic screening of commercial botanical products in 3T3-L1 adipocytes and db/db mice. J Med Food 2010, 13:535-547.
21. Hall A.J., Babish J.G., Darland G.K., Carroll B.J., Konda V.R., Lerman R.H., et al. Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry 2008, 69:1534-1547.
22. Konda V.R., Desai A., Darland G., Bland J.S., Tripp M.L. Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation. J Inflamm (Lond) 2009, 6:26.
23. Tripp M., Darland G., Lerman R., Lukaczer D., Bland J., Babish J. Hop and modified hop extracts have potent in vitro anti-inflammatory properties. Acta Hort 2005, 668:217-227.
24. Hu J.P., Nishishita K., Sakai E., Yoshida H., Kato Y., Tsukuba T., et al. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur J Pharmacol 2008, 580:70-79.
25. Li H., Miyahara T., Tezuka Y., Namba T., Suzuki T., Dowaki R., et al. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull 1999, 22:391-396.
26. Wei P., Jiao L., Qin L.P., Yan F., Han T., Zhang Q.Y. Effects of berberine on differentiation and bone resorption of osteoclasts derived from rat bone marrow cells. Zhong Xi Yi Jie He Xue Bao 2009, 7:342-348.
27. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008, 29:535-559.
28. Kanazawa I., Yamaguchi T., Yamamoto M., Yamauchi M., Yano S., Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2007, 18:1675-1681.
29. Lerman R.H., Minich D.M., Darland G., Lamb J.J., Schiltz B., Babish J.G., et al. Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial. Nutr Metab (Lond) 2008, 5:29.
30. White M.A., Whisenhunt B.L., Williamson D.A., Greenway F.L., Netemeyer R.G. Development and validation of the food-craving inventory. Obes Res 2002, 10:107-114.
31. Ware J.E., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
32. Greene J.G. Constructing a standard climacteric scale. Maturitas 1998, 29:25-31.
33. Clemens T.L., Chernausek S.D. Genetic strategies for elucidating insulin-like growth factor action in bone. Growth Horm IGF Res 2004, 14:195-199.
34. Yakar S., Rosen C.J. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 2003, 228:245-252.
35. Yakar S., Kim H., Zhao H., Toyoshima Y., Pennisi P., Gavrilova O., et al. The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting. Pediatr Nephrol 2005, 20:251-254.
36. Conti E., Carrozza C., Capoluongo E., Volpe M., Crea F., Zuppi C., et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004, 110:2260-2265.
37. Perez-Lopez F.R. Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas 2009, 62:248-262.
38. Hypponen E., Boucher B.J., Berry D.J. Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
39. Wells G., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD004523.
40. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD001155.
41. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD003376.
42. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90:1897-1899.
43. Seibel M.J. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
44. Frenkel B., Hong A., Baniwal S.K., Coetzee G.A., Ohlsson C., Khalid O., et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol 2010, 224:305-310.
45. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
46. Tripp M.L., Konda V.R., Darland G., Desai A., Chang J.L., Carroll B.J., et al. Rho-iso-alpha acids and tetrahydro-iso-alpha acids are selective protein kinase inhibitors which potently reduce inflammation in macrophages in vitro and in the collagen-induced rheumatoid arthritis model in vivo. Acta Hort. (ISHS) 2009, 848:221-234.
47. Kong W.J., Zhang H., Song D.Q., Xue R., Zhao W., Wei J., et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009, 58:109-119.
48. Bilik D., McEwen L.N., Brown M.B., Pomeroy N.E., Kim C., Asao K., et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010, 95:4560-4565.
49. Fernandez-Real J.M., Izquierdo M., Ortega F., Gorostiaga E., Gomez-Ambrosi J., Moreno-Navarrete J.M., et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009, 94:237-245.